Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2009-12-22

FDA Approved: LOTREL — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA overview of a supplemental application for Lotrel (amlodipine besylate and benazepril hydrochloride) submitted by Novartis, likely involving a label change …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LOTREL (amlodipine besylate and benazepril hydrochloride)

Snippet

SUPPL AP for LOTREL (AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE)